---
document_datetime: 2025-04-01 14:56:09
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/slenyto-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: slenyto-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.5215067
conversion_datetime: 2025-12-24 00:54:50.405085
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Slenyto

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                              |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------|
| II/0028              | Extension of indication to include treatment of insomnia in children and adolescents aged 6-17 with Attention-Deficit Hyperactivity Disorder (ADHD), where sleep hygiene measures have been insufficient, based on results from phase III study NEU_CH_7911 and literature. As a consequence, | 30/01/2025                          | 17/03/2025                                  | SmPC and PL                      | Please refer to the Scientific Discussion 'Slenyto H-C-4425- II-28'. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the RMP has also been approved. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                 |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------|
| II/0025            | Extension of indication to include treatment of neurogenetic disorders (e.g., Angelman syndrome, Rett syndrome, Tuberous sclerosis complex and Williams syndrome) for SLENYTO, based on Phase III study NEU_CH_7911, post-marketing data and literature; As a consequence, sections 4.1 and 4.8 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 25/07/2024 | 26/08/2024 | SmPC and PL | Please refer to Scientific Discussion 'Slenyto-H-C-4425-II- 25' |
| PSUSA/1963/ 202309 | Periodic Safety Update EU Single assessment - melatonin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/05/2024 | n/a        |             | PRAC Recommendation - maintenance                               |
| N/0027             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16/02/2024 | 22/07/2024 | PL          |                                                                 |

<div style=\"page-break-after: always\"></div>

| N/0024    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                 | 24/11/2023   | 22/07/2024   | PL                     |                                                                                                                                                                                                                                                                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0022/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                     | 15/08/2023   | n/a          |                        |                                                                                                                                                                                                                                                                       |
| IAIN/0023 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                       | 13/07/2023   | 22/07/2024   | Annex II and PL        |                                                                                                                                                                                                                                                                       |
| R/0021    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                          | 30/03/2023   | 05/06/2023   | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Slenyto in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0020/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name | 25/10/2022   | n/a          |                        |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                    | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                     |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1963/ 202009 | Periodic Safety Update EU Single assessment - melatonin                                                                                                                                                                                                                                       | 10/06/2021 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                   |
| II/0017            | The update of the product information to reflect information from children treated with Circadin during the French RTU program and the known safety profile of Circadin authorised for adults. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 18/02/2021 | 02/06/2022 | SmPC, Annex II and PL  | The Product Information is updated to reflect relevant information from paediatric French program and the known safety profile of Circadin in adults. For more information, please refer to the Summary of Product Characteristics. |
| IB/0018            | B.I.e.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supportive data                                                                                                                                                                   | 03/11/2020 | n/a        |                        |                                                                                                                                                                                                                                     |
| IA/0016            | B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form                                                             | 26/05/2020 | 21/04/2021 | SmPC, Labelling and PL |                                                                                                                                                                                                                                     |
| IB/0015            | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                       | 13/03/2020 | 21/04/2021 | SmPC                   |                                                                                                                                                                                                                                     |
| IB/0014            | B.I.e.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                         | 13/03/2020 | n/a        |                        |                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| II/0010   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 31/10/2019   | n/a        |      |                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-------------------------------|
| IB/0012   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/08/2019   | 24/02/2020 | SmPC | variation                     |
| N/0011    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/06/2019   | 24/02/2020 | PL   |                               |
|           | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.4.z - Change in the batch size (including batch | 03/06/2019   | n/a        |      | IB/0009/G size ranges) of the |
| IB/0008/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21/05/2019   | n/a        |      |                               |

<div style=\"page-break-after: always\"></div>

|         | operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation   |            |            |                        | manufacturing   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------|
| N/0007  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                              | 29/04/2019 | 24/02/2020 | PL                     |                 |
| T/0004  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                           | 04/01/2019 | 11/03/2019 | SmPC, Labelling and PL |                 |
| IB/0006 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                       | 19/02/2019 | 24/02/2020 | SmPC                   |                 |
| IB/0005 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                | 04/01/2019 | 11/03/2019 | SmPC and PL            |                 |
| IB/0003 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                       | 04/01/2019 | 11/03/2019 | SmPC                   |                 |
| IB/0002 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                                                                                                                                                                 | 16/11/2018 | 11/03/2019 | SmPC                   | variation       |

<div style=\"page-break-after: always\"></div>

| IB/0001   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   | 14/11/2018   | 11/03/2019   | SmPC, Labelling and PL   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|